BNB Chain has opened a community forum to gather input on NewL1, a new Layer 1 blockchain designed to handle trading, payments, and AI workloads with high performance targets like sub-50 millisecond preconfirmations and over 100,000 transactions per second. NewL1 will use BNB as its sole gas token and features innovations like TxStream to reduce front-running and privacy enhancements. A testnet is planned for late 2026, with mainnet expected in early 2027, marking a significant expansion beyond BNB Smart Chain's current capabilities.
BNB Chain's new Layer 1 blockchain NewL1 is opening for community input. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 20, 2026 07:21 WIB: 32 of 50 major cryptos rose today. Notable movers include CRV at Rp6.644 (+4.43%, 99% Sell), ATOM at Rp31.312 (+3.71%, 76% Buy), and DOT at Rp20.639 (+3.26%, 83% Sell).
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...
Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...
